License

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

Retrieved on: 
Friday, March 8, 2024

EMERYVILLE, Calif., March 08, 2024 (GLOBE NEWSWIRE) --  XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its fourth quarter and full year 2023 financial results and highlighted portfolio activities expected to drive long-term shareholder value.

Key Points: 
  • XOMA recorded total revenues of $1.8 million and $4.8 million for the fourth quarter and full year of 2023, respectively.
  • General and administrative (“G&A”) expenses were $7.3 million for the fourth quarter and $25.6 million for the full year of 2023.
  • In the fourth quarter of 2023, G&A expenses included $2.6 million in non-cash stock-based compensation expense, compared with $1.0 million in the fourth quarter of 2022.
  • In 2023, net loss for the fourth quarter and year ended December 31, 2023, was $20.1 million and $40.8 million, respectively.

CryptoBlox Signs Share Purchase Agreement to Acquire Blockchain Fintech

Retrieved on: 
Tuesday, March 5, 2024

Vancouver, B.C., March 05, 2024 (GLOBE NEWSWIRE) -- CryptoBlox Technologies Inc. (the “Company” or “CryptoBlox”) (CSE: BLOX) is pleased to announce that it has entered into a share purchase agreement, dated effective March 4, 2024 (the “Agreement”), to acquire (the “Acquisition”) Blockchain Fintech Unipessoal LDA (“Blockchain Fintech”), a Portuguese corporation that develops blockchain-based financial technologies that help onboard “average users” to the blockchain economy. Pursuant to the Agreement, the Company will acquire 100% of the outstanding shares of Blockchain Fintech for 20,000,000 common shares of the Company, having a deemed value of $11,000,000.

Key Points: 
  • Vancouver, B.C., March 05, 2024 (GLOBE NEWSWIRE) -- CryptoBlox Technologies Inc. (the “Company” or “CryptoBlox”) (CSE: BLOX) is pleased to announce that it has entered into a share purchase agreement, dated effective March 4, 2024 (the “Agreement”), to acquire (the “Acquisition”) Blockchain Fintech Unipessoal LDA (“Blockchain Fintech”), a Portuguese corporation that develops blockchain-based financial technologies that help onboard “average users” to the blockchain economy.
  • Pursuant to the Agreement, the Company will acquire 100% of the outstanding shares of Blockchain Fintech for 20,000,000 common shares of the Company, having a deemed value of $11,000,000.
  • On September 28, 2023, the Company announced the execution of a letter of intent with Blockchain Fintech, which contemplated a strategic partnership in which CryptoBlox would acquire the rights to Blockchain Fintech’s digital asset license then under development (the “License”).
  • Through Blockchain Fintech, the Company intends to build and launch structured digital asset products and blockchain payments services within Portugal and eventually other jurisdictions.

AllFi Technologies, Inc. (AllFi Tech), a Subsidiary of The Crypto Company, Completes License Deal, Paving the way for Expansion of the AllFi Brand

Retrieved on: 
Thursday, February 29, 2024

Through this strategic move, AllFi Tech has granted exclusive rights to AllFi Holdings LLC for the utilization of the AllFi brand.

Key Points: 
  • Through this strategic move, AllFi Tech has granted exclusive rights to AllFi Holdings LLC for the utilization of the AllFi brand.
  • In a collaborative effort, AllFi Tech has aligned forces with AllFi Holdings to empower the underbanked and unbanked communities through accessible financial solutions.
  • “This licensing deal marks a milestone for us,” stated Ron Levy, CEO of The Crypto Company.
  • “We are proud to empower AllFi Holdings in our mutual mission to reach underserved communities by promoting financial inclusion, while also empowering growth and recognition of the AllFi brand.”
    Under the License Agreement, AllFi Tech will receive royalties for the utilization of the AllFi brand.

WLAN Revenues Plummet 26 Percent in 4Q 2023, According to Dell'Oro Group

Retrieved on: 
Wednesday, March 6, 2024

REDWOOD CITY, Calif., March 6, 2024 /PRNewswire/ -- According to a recently published report from Dell'Oro Group, the trusted source for market information about the telecommunications, security, networks, and data center industries, 2023 was a roller coaster ride for Wireless LAN (WLAN) vendors. Revenues were elevated in the first half of the year but contracted sharply in 4Q 2023. Despite the end-of-year correction, annual WLAN revenues hit a record $10 B.

Key Points: 
  • Revenues were elevated in the first half of the year but contracted sharply in 4Q 2023.
  • Juniper Networks was an outlier in the WLAN market in 4Q, managing to grow Y/Y and Q/Q despite the difficult market conditions.
  • The percentage of 4Q 2023 revenues from the sale of Indoor Wi-Fi 6E APs was flat compared to 3Q 2023.
  • All regions experienced a Y/Y reduction in WLAN revenues, with sales to China contracting the least of all the macro regions.

Southwest Orthopaedic Specialists, PLLC Notifies of INTEGRIS Health Data Security Incident

Retrieved on: 
Saturday, March 2, 2024

OKLAHOMA CITY, March 1, 2024 /PRNewswire/ -- On February 7, 2024, INTEGRIS Health, which manages certain electronic health data on behalf of Southwest Orthopaedic Specialists, PLLC ("SOS"), notified SOS that a recent data privacy incident experienced by INTEGRIS Health may have impacted information belonging to certain SOS patients.

Key Points: 
  • OKLAHOMA CITY, March 1, 2024 /PRNewswire/ -- On February 7, 2024, INTEGRIS Health, which manages certain electronic health data on behalf of Southwest Orthopaedic Specialists, PLLC ("SOS"), notified SOS that a recent data privacy incident experienced by INTEGRIS Health may have impacted information belonging to certain SOS patients.
  • INTEGRIS Health is mailing letters to potentially impacted individuals, and no SOS systems were impacted by the INTEGRIS Health event.
  • Upon becoming aware of the suspicious activity, INTEGRIS Health took steps to secure the environment and commenced an investigation into the nature and scope of the activity.
  • Upon determination of the scope of potentially affected information, INTEGRIS commenced a detailed review of the relevant data to determine the type of information present and to whom that data related.

Hess Announces First Plush School Bus

Retrieved on: 
Friday, March 1, 2024

NEW YORK, March 1, 2024 /PRNewswire/ -- Hess today announced a new addition to its Hess Toy Truck collection -- the fifth in its plush toy series designed especially for its youngest fans.

Key Points: 
  • NEW YORK, March 1, 2024 /PRNewswire/ -- Hess today announced a new addition to its Hess Toy Truck collection -- the fifth in its plush toy series designed especially for its youngest fans.
  • My Plush Hess Truck: 2024 School Bus is now on sale exclusively at HessToyTruck.com for $35.99 with free standard shipping and Energizer® batteries included.
  • The 2024 commemorative license plate and accompanying personalizable keepsake School Bus Driver's License tag follows the Hess Toy Truck collectability tradition.
  • The My Plush Hess Truck series, offered exclusively online at HessToyTruck.com , is part of the bestselling Hess Toy Truck collection, a treasured holiday toy tradition celebrating its 60th Anniversary this year.

Oramed Letter to Shareholders

Retrieved on: 
Tuesday, February 20, 2024

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.
  • I am pleased to share with you an update regarding Oramed.
  • Oramed and HTIT Joint Venture:
    In January 2024, Oramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture ("JV"), centered around Oramed's cutting-edge oral drug delivery technology.
  • We thank you for your support and look forward to keeping our shareholders updated on the important milestones ahead.

ASP Isotopes Inc. Provides Update on Plans to Spin-Out its Wholly Owned Subsidiary, Quantum Leap Energy

Retrieved on: 
Friday, February 16, 2024

WASHINGTON, Feb. 16, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or “ASPI” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, announced today an update on its previously disclosed intention to spin-out its wholly owned subsidiary, Quantum Leap Energy LLC (“QLE”), as a separate public company. ASPI is planning to list QLE on a national exchange and distribute a portion of QLE’s common equity to ASPI’s stockholders as of a future record date, anticipated to be completed by year-end, in each case subject to obtaining applicable approvals and consents and complying with applicable rules and regulations and public market trading and listing requirements.

Key Points: 
  • - ASP Isotopes plans to spin a portion of Quantum Leap Energy’s common equity to ASP Isotopes' stockholders as of a future record date, in a tax efficient manner.
  • - ASP Isotopes licenses rights to technology related to the enrichment of nuclear fuels to Quantum Leap Energy.
  • ASPI to receive a 10% perpetual royalty on all revenues of Quantum Leap Energy.
  • - ASPI and QLE continue to work with potential customers to help resolve the current nuclear fuel supply chain issues.

BROADPEAK SA: Broadpeak reports annual revenue

Retrieved on: 
Tuesday, February 13, 2024

At 31 December, annual revenue amounted to €39m, compared with €41.9m in 2022, for a decrease of 6.8%.

Key Points: 
  • At 31 December, annual revenue amounted to €39m, compared with €41.9m in 2022, for a decrease of 6.8%.
  • This disappointing trend reflects tighter business conditions, with a marked wait-and-see attitude on the part of TV and telecom operators (accounting for over 80% of Broadpeak revenue).
  • The region ultimately posted an increase of 23.6%, for revenue of €4.7m, now accounting for 12% of the Group’s total business activity.
  • an increase in the contribution of recurring revenue, solid and sustainable growth, and a sharp increase in margins.

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

Retrieved on: 
Wednesday, February 7, 2024

In exchange, BridgeBio will receive an upfront payment of USD 100 million as well as royalties up to the high-twenties percent on sales of infigratinib in Japan, with the potential for additional milestone-based payments.

Key Points: 
  • In exchange, BridgeBio will receive an upfront payment of USD 100 million as well as royalties up to the high-twenties percent on sales of infigratinib in Japan, with the potential for additional milestone-based payments.
  • Infigratinib is an oral small molecule designed to inhibit FGFR3 and thus target FGFR3-driven skeletal dysplasias at their source, including achondroplasia and hypochondroplasia.
  • “By partnering with Kyowa Kirin, we hope to significantly accelerate the development of infigratinib to potentially provide options for children with achondroplasia, hypochondroplasia, and eventually skeletal dysplasias in Japan.
  • Based on the results from the latest clinical trials, we believe BridgeBio’s infigratinib has high potential for treating achondroplasia.